Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Vestibulum ante ipsum primis
$56.00Add to cartCras mollis dolor sed tempor iaculis. Duis ac ante quam. Donec nec justo erat. Nam a augue vel ex venenatis interdum sit amet ac quam. Interdum et malesuada fames ac ante ipsum primis in faucibus. Vestibulum erat lectus, cursus at dui in, fringilla commodo lectus. Quisque eu bibendum quam, eget euismod sem
-
Quick View
Nulla feugiat felis tempor sem
$61.00Add to carteget ullamcorper leo auctor. Donec at interdum nibh, in blandit massa. Nam pulvinar mollis quam, vel fringilla mi interdum elementum. Donec ullamcorper turpis et libero sagittis vestibulum. Donec enim nisl, rhoncus vitae magna eu, convallis tempus tortor. Integer et facilisis metus.
-
Quick View
Phasellus varius turpis
$56.00Add to cartPhasellus varius turpis consequat enim tincidunt, id aliquam orci hendrerit. Curabitur quis accumsan nisl, in condimentum magna. Fusce nec diam et dolor ornare rhoncus nec ut mauris. In eleifend mi in felis dictum fermentum. Morbi vel arcu sit amet dolor venenatis bibendum in eu dui.
-
Quick View
Curabitur ultricies ante ultricies blandit
$88.00Add to cartCurabitur ultricies ante ultricies blandit placerat. Phasellus fermentum, ligula sed vestibulum blandit, mi odio laoreet sem, a venenatis tellus felis eu justo. Nullam ut felis et mauris iaculis malesuada. Donec non turpis vel lectus accumsan rutrum. Vestibulum finibus nunc libero, vel dapibus mauris porta vitae.
Reviews
There are no reviews yet.